LUMO Lumos Pharma Inc
5,116
$2.43
$0.1401
(5.45%)
| Watchers | 5,116 |
| 52-Wk Low | $2.01 |
| 52-Wk High | $4.55 |
| Market Cap | $20.86M |
| Volume | 12,153.00 |
| 52-Wk High | $4.55 |
| 52-Wk Low | $2.01 |
Lumos Pharma (NASDAQ:LUMO) Earns Buy Rating from HC WainwrightTicker Report • 2 months ago
HC Wainwright reissued their buy rating on shares of Lumos Pharma (NASDAQ:LUMO Free Report) in a report published on Wednesday morning, Benzinga reports. They currently have a $28.00 target...
Share to Feed
AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency...
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Poseida Therapeutics (PSTX Research Report), Lumos Pharma...
End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201...
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD...
AUSTIN, Texas, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone...
AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit Duke...